Evidence map›Paper›PMID 27903673›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.

Katrien Van Roosbroeck, Francesca Fanini, Tetsuro Setoyama, Cristina Ivan, Cristian Rodriguez-Aguayo, Enrique Fuentes-Mattei, Lianchun Xiao, Ivan Vannini, Roxana S Redis, Lucilla D'Abundo and 30 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 1 synthesis or guideline pooled it, 183 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Therapeutic Applications of Poly-miRNAs and miRNA Sponges.International journal of molecular sciences · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  19. Article
  20. Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors at 12 institutions in 5 countries.

Katrien Van Roosbroeck *Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Francesca Fanini *Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l. IRCCS, Unit of Gene Therapy, Meldola (FC) 47014, Italy.
Tetsuro Setoyama *Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cristina IvanCenter for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cristian Rodriguez-AguayoDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Enrique Fuentes-MatteiDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Lianchun XiaoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ivan VanniniIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l. IRCCS, Unit of Gene Therapy, Meldola (FC) 47014, Italy.
Roxana S RedisDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Lucilla D'AbundoDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Xinna ZhangCenter for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Milena S NicolosoDivision of Experimental Oncology 2, CRO, National Cancer Institute, Aviano 33081, Italy.
Simona RossiDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Vianey Gonzalez-VillasanaDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Rajesha RupaimooleDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Manuela FerracinDepartment of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, Bologna 40126, Italy.
Fortunato MorabitoDepartment of Onco-Hematology, A.O. of Cosenza, Cosenza 87100, Italy.
Antonino NeriDepartment of Clinical Sciences and Community Health, University of Milano and Hematology, Ospedale Policlinico, Milano 20122, Italy.
Peter P RuvoloDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Vivian R RuvoloDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Chad V PecotDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Dino AmadoriIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l. IRCCS, Unit of Gene Therapy, Meldola (FC) 47014, Italy.
Lynne AbruzzoDepartment of Pathology, The Ohio State University, Columbus, OH 43210, USA.
Steliana CalinDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Xuemei WangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
M James YouDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Alessandra FerrajoliDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Robert OrlowskiDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
William PlunkettDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Tara M LichtenbergDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ramana V DavuluriDepartment of Preventive Medicine - Division of Health and Biomedical Informatics, Northwestern University - Feinberg School of Medicine, Chicago, IL 60611, USA.
Ioana Berindan-NeagoeDepartment of Functional Genomics, The Oncology Institute, 400015 Cluj-Napoca, Romania.
Massimo NegriniDepartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara 44121, Italy.
Ignacio I WistubaDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hagop M KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Anil K SoodCenter for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Gabriel Lopez-BeresteinDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Michael J KeatingDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Muller FabbriDepartments of Pediatrics and Molecular Microbiology & Immunology, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Saban.
George A CalinDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · USIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITAzienda Ospedaliera di Cosenza · ITChildren's Hospital of Los Angeles · USFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITIuliu Hațieganu University of Medicine and Pharmacy · RONational Cancer Institute · UANationwide Children's Hospital · USNorthwestern University · USThe Ohio State University · USUniversity of Bologna · ITUniversity of Ferrara · IT

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9M
Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8M
University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y · 2003 to 2023
$43.7M
Tropism Enhanced Oncolytic Adenovirus for the Treatment of Brain TumorsP50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Juan Fueyo · 2008 to 2026
$41.2M
UT M.D. Anderson Cancer Center SPORE in MelanomaP50CA093459 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GRIMM, ELIZABETH A · 2004 to 2014
$23.7M
Texas Center for Cancer NanomedicineU54CA151668 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2010 to 2014
$12.4M
Center for Clinical and Translational Sciences (CCTS)KL2TR000370 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$4.3M
Novel extra cellular RNA-based combinatorial RNA inhibition therapyUH3TR000943 · NCATS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LOPEZ-BERESTEIN, GABRIEL · 2015 to 2017
$3.2M
Protein-coding and non-coding RNA biomarkers for early detection of CLLR01CA182905 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ABRUZZO, LYNNE V., CALIN, GEORGE A. · 2014 to 2018
$2.9M
Informatics Platform for Mammalian Gene Regulation at Isoform-levelR01LM011297 · NLM · WISTAR INSTITUTE · PI DAVULURI, RAMANA V · 2013 to 2020
$2.4M
NCATS NIH HHS KL2 TR000370NCATS NIH HHS UH2 TR000943NCATS NIH HHS UH3 TR000943NCATS NIH HHS UL1 TR001422NCI NIH HHS P30 CA010815NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA093459NCI NIH HHS P50 CA100632NCI NIH HHS P50 CA127001NCI NIH HHS R01 CA135444NCI NIH HHS R01 CA182905NCI NIH HHS U54 CA151668NLM NIH HHS R01 LM011297
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntagomirsCell Line, TumorCisplatinDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansLung NeoplasmsMiceMicroRNAsTumor Suppressor Protein p53AntagomirsCisplatinMicroRNAsMIRN155 microRNA, humanTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID27903673
PMCPMC5449263
OpenAlexW2559239118

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.